Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings
Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.
Data from the following clinical trials are discussed:
- ASCO 7521: ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
- EHA P1120: The Efficacy and Safety of Zanubrutinib and Dexamethasone in Symptomatic Waldenstrom Macroglobulinemia
- EHA P1160: Results of a Phase 2 Expanded Access Study of Zanubrutinib in Patients with Waldenstrom Macroglobulinemia
- ASCO 7510: Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial
- ASCO 7511: Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL
- ASCO 7524: Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
Related Videos
Related Content
